MANUFACTURER: Alexion Pharmaceuticals

USAGE: Intravenous

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Pharmaceuticals and Medical Devices Agency (PMDA)

Ultomiris (ravulizumab) is a medication for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adults. Its mechanism of action involves targeting complement protein C5 as it inhibits its activation, which may lead to hemolysis.